Sanofi upgrades 2021 guidance once again – Dupixent drives growth
On Thursday morning, French Sanofi published its report for the third quarter of the year, and in connection with the release, the pharmaceutical company upgrades its earnings-per-share expectations for the full year.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
The French pharmaceutical company Sanofi has upgraded its 2021 financial guidance for earnings per share (business EPS), it reports in a press release on Thursday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New Sanofi study is yet another win for blockbuster drug
For subscribers
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
